Eight patients had extensive analysis of their PBMCs for tumor-specific T-cell responses, and six of these eight patients developed T-cells specific for multiple tumor-associated antigens that were not included in the vaccine, such as PAP, MUC-1, PSMA, and PSCA (78). Here, FOLH1 is linked to neoplasm.